Comparative Pharmacology
Head-to-head clinical analysis: E MYCIN E versus ERYTHROMYCIN LACTOBIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E MYCIN E versus ERYTHROMYCIN LACTOBIONATE.
E-MYCIN E vs ERYTHROMYCIN LACTOBIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptide chains.
Erythromycin lactobionate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing the translocation of peptides. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
250-500 mg orally every 6 hours or 333-500 mg every 8 hours; maximum 4 g/day.
1-4 g/day IV divided every 6 hours; maximum 4 g/day. Infuse over 20-60 minutes.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Terminal elimination half-life: 1.4-2.0 hours in adults with normal renal function. In patients with anuria, half-life may be prolonged up to 4.8-6.0 hours.
Primarily excreted unchanged in urine (70-80%) via glomerular filtration and tubular secretion; 15-20% excreted in feces via biliary elimination.
Primarily biliary excretion (80-90% as unchanged drug and metabolites); renal excretion accounts for 10-15% of the dose. Fecal elimination is minimal (<5%).
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic